In a move to grapple with seemingly endless increases in healthcare spending, the U.S. healthcare industry is in the midst of undergoing a fundamental transformation in the way physicians are ...
MUNICH, October 19, 2025--(BUSINESS WIRE)--Tubulis today announced positive early clinical data from its NAPISTAR1-01 Phase I/IIa study (NCT06303505) in a late-breaking oral presentation at the ...
Corcept Therapeutics Incorporated's relacorilant met the primary endpoint in the phase 3 ROSELLA study for platinum-resistant ovarian cancer patients, boosting shares by over 90% the very same day.
(RTTNews) - AbbVie (ABBV) announced that final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE or mirvetuximab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback